Cargando…

Risk prediction of developing venous thrombosis in combined oral contraceptive users

BACKGROUND: Venous thromboembolism (VTE) is a complex multifactorial disease influenced by genetic and environmental risk factors. An example for the latter is the regular use of combined oral contraceptives (CC), which increases the risk to develop VTE by 3 to 7 fold, depending on estrogen dosage a...

Descripción completa

Detalles Bibliográficos
Autores principales: McDaid, Aaron, Logette, Emmanuelle, Buchillier, Valérie, Muriset, Maude, Suchon, Pierre, Pache, Thierry Daniel, Tanackovic, Goranka, Kutalik, Zoltán, Michaud, Joëlle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531518/
https://www.ncbi.nlm.nih.gov/pubmed/28750087
http://dx.doi.org/10.1371/journal.pone.0182041
_version_ 1783253376964755456
author McDaid, Aaron
Logette, Emmanuelle
Buchillier, Valérie
Muriset, Maude
Suchon, Pierre
Pache, Thierry Daniel
Tanackovic, Goranka
Kutalik, Zoltán
Michaud, Joëlle
author_facet McDaid, Aaron
Logette, Emmanuelle
Buchillier, Valérie
Muriset, Maude
Suchon, Pierre
Pache, Thierry Daniel
Tanackovic, Goranka
Kutalik, Zoltán
Michaud, Joëlle
author_sort McDaid, Aaron
collection PubMed
description BACKGROUND: Venous thromboembolism (VTE) is a complex multifactorial disease influenced by genetic and environmental risk factors. An example for the latter is the regular use of combined oral contraceptives (CC), which increases the risk to develop VTE by 3 to 7 fold, depending on estrogen dosage and the type of progestin present in the pill. One out of 1'000 women using CC develops thrombosis, often with life-long consequences; a risk assessment is therefore necessary prior to such treatment. Currently known clinical risk factors associated with VTE development in general are routinely checked by medical doctors, however they are far from being sufficient for risk prediction, even when combined with genetic tests for Factor V Leiden and Factor II G20210A variants. Thus, clinical and notably genetic risk factors specific to the development of thrombosis associated with the use of CC in particular should be identified. METHODS AND FINDINGS: Step-wise (logistic) model selection was applied to a population of 1622 women using CC, half of whom (794) had developed a thromboembolic event while using contraceptives. 46 polymorphisms and clinical parameters were tested in the model selection and a specific combination of 4 clinical risk factors and 9 polymorphisms were identified. Among the 9 polymorphisms, there are two novel genetic polymorphisms (rs1799853 and rs4379368) that had not been previously associated with the development of thromboembolic event. This new prediction model outperforms (AUC 0.71, 95% CI 0.69–0.74) previously published models for general thromboembolic events in a cross-validation setting. Further validation in independent populations should be envisaged. CONCLUSION: We identified two new genetic variants associated to VTE development, as well as a robust prediction model to assess the risk of thrombosis for women using combined oral contraceptives. This model outperforms current medical practice as well as previously published models and is the first model specific to CC use.
format Online
Article
Text
id pubmed-5531518
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55315182017-08-07 Risk prediction of developing venous thrombosis in combined oral contraceptive users McDaid, Aaron Logette, Emmanuelle Buchillier, Valérie Muriset, Maude Suchon, Pierre Pache, Thierry Daniel Tanackovic, Goranka Kutalik, Zoltán Michaud, Joëlle PLoS One Research Article BACKGROUND: Venous thromboembolism (VTE) is a complex multifactorial disease influenced by genetic and environmental risk factors. An example for the latter is the regular use of combined oral contraceptives (CC), which increases the risk to develop VTE by 3 to 7 fold, depending on estrogen dosage and the type of progestin present in the pill. One out of 1'000 women using CC develops thrombosis, often with life-long consequences; a risk assessment is therefore necessary prior to such treatment. Currently known clinical risk factors associated with VTE development in general are routinely checked by medical doctors, however they are far from being sufficient for risk prediction, even when combined with genetic tests for Factor V Leiden and Factor II G20210A variants. Thus, clinical and notably genetic risk factors specific to the development of thrombosis associated with the use of CC in particular should be identified. METHODS AND FINDINGS: Step-wise (logistic) model selection was applied to a population of 1622 women using CC, half of whom (794) had developed a thromboembolic event while using contraceptives. 46 polymorphisms and clinical parameters were tested in the model selection and a specific combination of 4 clinical risk factors and 9 polymorphisms were identified. Among the 9 polymorphisms, there are two novel genetic polymorphisms (rs1799853 and rs4379368) that had not been previously associated with the development of thromboembolic event. This new prediction model outperforms (AUC 0.71, 95% CI 0.69–0.74) previously published models for general thromboembolic events in a cross-validation setting. Further validation in independent populations should be envisaged. CONCLUSION: We identified two new genetic variants associated to VTE development, as well as a robust prediction model to assess the risk of thrombosis for women using combined oral contraceptives. This model outperforms current medical practice as well as previously published models and is the first model specific to CC use. Public Library of Science 2017-07-27 /pmc/articles/PMC5531518/ /pubmed/28750087 http://dx.doi.org/10.1371/journal.pone.0182041 Text en © 2017 McDaid et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
McDaid, Aaron
Logette, Emmanuelle
Buchillier, Valérie
Muriset, Maude
Suchon, Pierre
Pache, Thierry Daniel
Tanackovic, Goranka
Kutalik, Zoltán
Michaud, Joëlle
Risk prediction of developing venous thrombosis in combined oral contraceptive users
title Risk prediction of developing venous thrombosis in combined oral contraceptive users
title_full Risk prediction of developing venous thrombosis in combined oral contraceptive users
title_fullStr Risk prediction of developing venous thrombosis in combined oral contraceptive users
title_full_unstemmed Risk prediction of developing venous thrombosis in combined oral contraceptive users
title_short Risk prediction of developing venous thrombosis in combined oral contraceptive users
title_sort risk prediction of developing venous thrombosis in combined oral contraceptive users
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531518/
https://www.ncbi.nlm.nih.gov/pubmed/28750087
http://dx.doi.org/10.1371/journal.pone.0182041
work_keys_str_mv AT mcdaidaaron riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers
AT logetteemmanuelle riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers
AT buchilliervalerie riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers
AT murisetmaude riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers
AT suchonpierre riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers
AT pachethierrydaniel riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers
AT tanackovicgoranka riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers
AT kutalikzoltan riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers
AT michaudjoelle riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers